{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-091503","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.452065+00:00","generated_at":"2026-05-15T21:47:52.899504+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PepGen reports FY2025 net loss $89.7M; FDA partial hold on FREEDOM2 trial","bullets":["FDA placed partial clinical hold on FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1; questions relate to preclinical studies, not clinical data.","Dosing of 10 mg/kg cohort continues in Canada and UK; no US patients enrolled. 5 mg/kg data expected Q1 2026, 10 mg/kg data 2H 2026.","Cash and marketable securities $148.5M as of Dec 31, 2025, sufficient into H2 2027. Net loss $89.7M for FY2025 ($2.12 per share).","Appointed Joseph Vittiglio as Chief Business and Legal Officer in December 2025.","USPTO issued composition-of-matter patent for PGN-EDODM1, providing US exclusivity into H2 2042."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-091503","json":"https://secwatch.observer/filing/0001193125-26-091503.json","markdown":"https://secwatch.observer/filing/0001193125-26-091503.md","text":"https://secwatch.observer/filing/0001193125-26-091503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526091503/0001193125-26-091503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526091503/pepg-20260304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:47:52.899504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec122aacf4ad04bec89e1798302f7fe36a4433a6","claim":"PepGen Inc. reported financial results for the quarter and year-ended December 31, 2025.","evidence_excerpt":"PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526091503/0001193125-26-091503-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year-ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}